1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
Europe Heparin Market By Type, By Application, By Route of Administration, By End Use, By Country, Growth Potential, COVID-19 Impact Analysis Report and Forecast, 2021 - 2027

Europe Heparin Market By Type, By Application, By Route of Administration, By End Use, By Country, Growth Potential, COVID-19 Impact Analysis Report and Forecast, 2021 - 2027

  • June 2021
  • 94 pages
  • ID: 6131390
  • Format: PDF
  • KBV Research

Summary

Table of Contents

The Europe Heparin Market would witness market growth of 6.2% CAGR during the forecast period (2021-2027).

The demand for anticoagulants is very high and it is anticipated to boost the overall heparin market. Moreover, the increased healthcare expenditures and growing awareness levels among the patient are the major factors expected to drive the global heparin market over the forecast period.

The growing burden of chronic diseases is the main factor for the growth of the heparin market. As per the World Health Organization, chronic diseases are a massive global challenge for decades and account for almost 60% of all deaths across the globe. The worldwide burden of chronic diseases may reach 57% by the end of 2020.

In the past few decades, it has been reported that there are increasing incidences of venous thrombosis and cardiovascular diseases across the globe including heart attacks and strokes. It is the major factor that is driving the growth of the global heparin market. Moreover, as heparin is used in various surgeries including orthopaedic and heart surgeries, and rise in the number of patients undergoing such surgeries would further boost the growth of the heparin market. Cardiovascular diseases have a direct impact on the heparin market growth.

The demand for heparin is high in European counties. It is due to the increasing adoption of technologically advanced products in the healthcare sector in this region. The increasing number of patients who are suffering from cardiovascular diseases is very high among the region’s population. This will open new growth avenues in the heparin market in this region. The medical infrastructure is very advanced in the UK. The whole population’s medical expenses are covered by the National Health System. It is financed through general taxation and independently-run by the Department of Health. The major cause of death in the UK is due to coronary heart disease (CHD). The use of heparin in the treatment of CHD is increasing exponentially. Thus, it is expected that the demand for heparin will increase in the forecast period and positively contribute to the growth of the market. Although there is a decline in death rates due to cardiovascular disease (CVD) in the UK, rates are still comparatively high than other Western European countries.

The Germany market dominated the Europe Venous Thromboembolism Market by Country 2020, thereby, achieving a market value of $100.2 million by 2027. The UK market is exhibiting a CAGR of 6.7% during (2021 - 2027). Additionally, The France market is poised to grow at a CAGR of 8.2% during (2021 - 2027).

Based on Type, the market is segmented into Low Molecular Weight Heparin, Unfractionated Heparin and Ultra-low Molecular Weight Heparin. Based on Application, the market is segmented into Atrial Fibrillation, Coronary Artery Disease, Venous Thromboembolism, Renal Impairment and Other Applications. Based on Route of Administration, the market is segmented into Subcutaneous and Intravenous. Based on End Use, the market is segmented into Outpatient and Inpatient. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Baxter International, Inc., B. Braun Melsungen AG, Fresenius SE & Co. KGaA, Pfizer, Inc., Sanofi S.A., Teva Pharmaceuticals Industries Ltd., Hebei Changshan Biochemical Pharmaceutical Co., Ltd., Dr. Reddy’s Laboratories Ltd., LEO Pharma A/S, and Viatris, Inc.

Scope of the Study

Market Segments covered in the Report:

By Type

• Low Molecular Weight Heparin

• Unfractionated Heparin

• Ultra-low Molecular Weight Heparin

By Application

• Atrial Fibrillation

• Coronary Artery Disease

• Venous Thromboembolism

• Renal Impairment

• Other Applications

By Route of Administration

• Subcutaneous

• Intravenous

By End Use

• Outpatient

• Inpatient

By Country

• Germany

• UK

• France

• Russia

• Spain

• Italy

• Rest of Europe

Companies Profiled

• Baxter International, Inc.

• B. Braun Melsungen AG

• Fresenius SE & Co. KGaA

• Pfizer, Inc.

• Sanofi S.A.

• Teva Pharmaceuticals Industries Ltd.

• Hebei Changshan Biochemical Pharmaceutical Co., Ltd.

• Dr. Reddy’s Laboratories Ltd.

• LEO Pharma A/S

• Viatris, Inc.

Unique Offerings

• Exhaustive coverage

• Highest number of market tables and figures

• Subscription based model available

• Guaranteed best price

• Assured post sales research support with 10% customization free

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.

ref:plp2021

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on